SecBot SecBot
8-K ·Filed Mar 12, 2026

SLDB

Solid Biosciences Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago SEC0001193125-26-102489
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

This data strengthens SGT-003's differentiation and supports potential for accelerated approval. Traders should monitor upcoming FDA meetings in H1 2026 for guidance on accelerated approval pathway and mid-2026 clinical updates.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.71
T+0 close · Mar 12, 2026 · via day close
Latest settled
−13.10%
T+60 · $6.70
Vs SPY
−23.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 12 $7.71entry
  2. T+1 · 8mo ago −5.19%α −4.59% · $7.31
  3. T+5 · 8mo ago −7.65%α −6.67% · $7.12
  4. T+20 · 7mo ago +4.02%α +2.05% · $8.02
  5. T+60 · 5mo ago −13.10%α −23.80% · $6.70
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Solid Biosciences announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, showing robust microdystrophin expression and biomarker improvements in Duchenne muscular dystrophy patients. The company also confirmed FDA alignment on the Phase 3 IMPACT DUCHENNE trial design, with dosing expected to begin in Q1 2026.

Key Facts

  • SGT-003 showed 60% mean microdystrophin expression by western blot at Day 90 (n=19), increasing to 91% at Day 360 (n=3)
  • Mean vector copies per nucleus were 11 at Day 90 and 12 at Day 360, indicating stable transduction
  • Key biomarkers showed significant improvement: 38% mean reduction in serum creatine kinase (CK) at Day 90, 44% reduction in eMHC-positive fibers suggesting disruption of degeneration-regeneration cycle
  • FDA has agreed the Phase 3 IMPACT DUCHENNE trial design is reasonable, with dosing expected in Q1 2026
  • SGT-003 is the only microdystrophin therapy with the R16/R17 binding domain that localizes nNOS to muscle

Financial Impact

No direct financial impact disclosed, but clinical progress significantly de-risks development path for SGT-003

pipeline valuedevelopment riskmarket potential

Risk Factors

  • Interim data from small samples (n=3 at Day 360) may not be predictive of final outcomes
  • Phase 3 trial results may not replicate Phase 1/2 findings
  • Company remains dependent on raising substantial additional capital to continue development

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-102489
Document: 0001193125-26-102489-index-headers.html0001193125-26-102489
Document: 0001193125-26-102489-index.html0001193125-26-102489
Document: 0001193125-26-102489.txt0001193125-26-102489

Track record

14 reports on SLDB

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +20.77% at T+20 after the Mar 19, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.84 Now $6.48 −5.26% settles Dec 15
  2. Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $7.02 Now $6.48 −7.69% settles Dec 8
  3. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $6.18 Now $6.48 +4.85% settles Dec 4
  4. Aug 6, 202614w ago S-3ASR Neutral 4/10 Entry $8.39 to $10.25 Now $6.48 −22.77% ▲ +22.17% +22.57% vs SPY
  5. May 12, 202626w ago Press Release Bearish 6/10 Entry $7.38 to $7.22 Now $6.48 +12.20% ▲ +2.17% +1.56% vs SPY
  6. May 7, 202627w ago Press Release Bullish 7/10 Entry $7.07 to $6.85 Now $6.48 −8.35% ▼ −3.11% −6.25% vs SPY
  7. Apr 23, 202629w ago DEFA14A Neutral 3/10 Entry $7.92 to $6.50 Now $6.48 −18.18% ▼ −17.93% −21.96% vs SPY
  8. Apr 10, 202631w ago 8-K Neutral 2/10 Entry $8.39 to $7.68 Now $6.48 −22.77% ▼ −8.46% −16.19% vs SPY
  9. Apr 1, 202632w ago EFFECT Bearish 7/10 Entry $7.38 to $7.05 Now $6.48 +12.20% ▲ +4.47% +14.19% vs SPY
  10. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $7.03 to $8.49 Now $6.48 −7.82% ▲ +20.77% +11.45% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 12, 2026